TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Presence of chronic venous insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants receiving 3 Medication Appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage Adherence to PrEP Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self reported PrEP Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants reporting Adherence to HIV testing recommendation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Difference between endoscopic gross tumor volume contours and standard gross tumor volume contours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Difference between inter-observer variation of endoscopic gross tumor volume and standard gross tumor volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: SPEED Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recurrence of C. difficile infection
Endpoint domain: Adverse events/effects
Primary endpoint: Coronary heart disease including acute myocardial infarction and death from CHD
Endpoint domain: Mortality/survival
Primary endpoint: Attention and psychomotor speed
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Tumor permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of micturition frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of needle attempts needed for block placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: collagen biosynthesis and breakdown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cone Sensitivity Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chromatic Contrast Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline fraction anisotropy of corticoreticular tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: hospitalized and/or severe virologically confirmed dengue
Endpoint domain: Mortality/survival
Primary endpoint: survival after thawing
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Treatment-Emergent AEs (TEAE) or a Serious AE
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients tolerant to stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No increase in pain
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance of methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of incidences and severity of Adverse Events (AE) and Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of cardiovascular death, first occurrence of myocardial infarction, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Composite of cardiovascular death, first occurrence of myocardial infarction, stroke, or severe ischemia requiring urgent intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of treatment-emergent AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Fugl Meyer Assessment on Upper Extremity (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of hemorrhagic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in COPM scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EEG power in alpha band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG power in beta band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fNIRS haemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: First cycle dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful Detoxification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Drug Use Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Illicit Drug Use Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete clinical recovery from Bell's palsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in area under the plasma concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P300 test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Solicited local and general adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events of special interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Functional progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binary Restenosis Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: heart transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Rivaroxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Time (AUClast) of Rivaroxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to Extrapolated Infinite Time (AUCinfinity) of Rivaroxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of HPPH
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of CYP450 2D6 phenotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of uncovered stent struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of malapposed stent struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of neointimal hyperplasia proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rescue intubation needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Bulbar Conjunctival Hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Change in Ocular Discomfort Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Positive P acnes culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Patients Who Experienced Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Panobinostat in Stratum 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Panobinostat in Stratum 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported treatment satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with solicited injection site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with solicited systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Grade 3 fever
Endpoint domain: Adverse events/effects
Primary endpoint: radical resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent of Excess Weight Loss (%EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of FMISO-PET for hypoxia visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause hospitalization rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Glucose rate of disposal (glucose Rd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of aortic atheromatous disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of severe atheromatous disease (grade 4 & 5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CMV DNAemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total Number of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life scoring
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevention of iron deficiency anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: binocular Distance Corrected Near Visual Acuity (DCNVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of antibodies against coronaviruses isolated and identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of blood units administered postoperation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hemoglobin levels measured in gr/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of etiologic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Complete Remission Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Perioral Rhytids Severity Rating Scale (PR-SRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of time mechanically ventilated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to first sensation of pain at the surgical site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Point Prevalence Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resting State Blood Oxygen Level Dependent (BOLD) Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Oxygen Level Dependent (BOLD) Signal During Flexion/Extension Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Oxygen Level Dependent (BOLD) Signal During Quadriceps Contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Oxygen Level Dependent (BOLD) Signal During Pain Inducing Tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Edinburgh Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebral Neurologic Event
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic Thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Death From Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Change in diameters of mammarian arteries and radial arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GLP-1 response as incremental area under curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma disappearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients Condition at Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with PRP titer ≥1 ϻg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent time pH > 4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of deaths in children aged 6 to 59 months
Endpoint domain: Mortality/survival
Primary endpoint: Total Scores of Parents' Perception of Uncertainty Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in frequency of menstrual disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: No sex or safe sex at last intercourse
Endpoint domain: Adverse events/effects
Primary endpoint: Coefficient of Fat Absorption (CFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Reporting 1 or More Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mammary lesions Visualization on ultrafast injected dynamic MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mammary lesions Visualization with a diffusion sequence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects experiencing severe (Grade 3) solicited injection site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects experiencing severe solicited systemic reactions (Grade 3)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects experiencing severe (Grade 3) clinical laboratory values
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects spontaneously reporting adverse events considered associated with the vaccination that are severe (Grade 3)
Endpoint domain: Adverse events/effects
Primary endpoint: Serious adverse events considered associated with the vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change of liver function parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total perioperative allogenic transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Correct placement in the superior caval vein during PICC insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: area under plasma drug concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time at max concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: half life (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Management outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients with improved LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: levels of folate in the perioperative serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: levels of homocysteine in the perioperative serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Morphological changes of H. pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diffusion Weight Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Oxygen Level Dependent Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1rho Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Contrast Enhanced Magnetic Resonance Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transformation of MPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: progression of liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thrombosis events
Endpoint domain: Adverse events/effects
Primary endpoint: haemorrhage events
Endpoint domain: Adverse events/effects
Primary endpoint: Nicotine pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability and feasibility on the UsExQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: maximum-tolerated dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Birth weight at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal morbidity (Crib Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Anti-Xa Levels Within Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute inspiratory capacity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Performance in a facial expression recognition task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sensory recovery in the reconstructed breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for mechanical ventilation, transfer to ICU or death within 21 days
Endpoint domain: Mortality/survival
Primary endpoint: The onset of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The complete motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The full motor recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Platelet transfusion independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Late complications post coarctation repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of RTA 744 Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Composition of microbiome in sputa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patient samples collected per year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Osteoarthritis Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number and incidence of subjects with Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 5 and 25% contrast visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Acute respiratory distress syndrome (ARDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in esophageal sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cmax - Maximum observed concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax - Time corresponding to occurrence of Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T½ - Apparent terminal elimination half life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial systemic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical benefit rate (CBR)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Bladder Control Scale (BLCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Evoked Potential and Ocular Tomography Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in MS Quality of Life Questionnaire (Physical Score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in mathematical reasoning scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bioavailability of disulfiram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma Fatty Acid Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipoprotein Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: proportion of participants with clinically evident CSF leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes